ESG Report

Overview

The report describes the company's 2023 drug-development and sustainability performance, including approval of its first Class 1.1 natural new drug in China and inclusion in the Dow Jones Sustainability Indices. It reports consolidated Scope 1 and Scope 2 inventories for the parent and subsidiaries, with DNV verification and recalculation of the 2021 baseline and FY2022 data. The company also set a 2025 goal to remove or offset all Scope 1 and Scope 2 emissions to reach carbon neutrality.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Publication date: 1 August 2024
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services